About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

buy.

agreed.. news could be today or tomorrow.. I prefer today for weekend press

iRX Broker :

20-Sep-06 ---Charles Stanley Buy 0.29p - -Which was a Reiteration of its previous stance ---source Barclays

Broker changed on 22 Sept to Seymour Pierce Ellis as its sole broker

present market capitalisation ?8.17million based on shares in issue of 2.726billion (the part to concentrate on is the Market Cap "?8.17million" NOT the number of shares, that really does not matter, It is the company Market Capitalisation which counts.

Director share holdings & options (these are all I can find, so may not be conclusive )

EiRx Therapeutics PLC 31 March 2004 EiRx Therapeutics plc ("the Company") Ordinary Shares of 2p each Ian Hayes, Chief Executive Officer of the Company, has today purchased 73,000 Ordinary Shares at a price of 6.75 pence per share. Ian Hayes now holds 73,000 Ordinary Shares representing 0.06 per cent. of the Company's issued share capital.
(The above figures were before the 10 for 1 split)



Grant of options

EiRx Therapeutics PLC

08 April 2004

EiRx Therapeutics plc ("the Company")



Grant of options over Ordinary Shares of 2 pence each.

The Company announces that it has granted options over 6,117,500 Ordinary Sharesto directors and staff of EiRx Therapeutics plc, representing 4.8 per cent. of the Company's issued share capital. ( THIS WOULD NOW BE LESS THAN 4.8% DUE TO DILUTION ) These options replace options held under an earlier cancelled scheme whereby employees could subscribe for shares in EiRx Therapeutics Limited, the Company's Irish based subsidiary. The options may be exercised at any date between 19 January 2005 and 19 January 2011 at a price of 7 pence per share,( THIS WOULD NOW BE 0.7p PER SHARE) the approximate mid-market price on 19 January 2004, the date the board agreed to grant these options. Included in the 6,117,500 options were

the following granted to directors: ( NOTE figs below adjusted for 10-1 split on 03rd Feb 2006 )



Name Position Number

John Pool Chairman 8,059,810

Ian Hayes ( NOW RETIRED ) Chief Executive 33,187,440

Finbarr Murphy Research Director 7,587,700

Nick Strong Finance Director 7,587,700

( NOTE THE OPTIONS EXERCISE PRICE WOULD NOW BE 0.7p ) so it is in their interest to get the share price well above that figure.



TAKEN FROM PRELIMINARY RESULTS FOR THE YEAR ENDED 30 JUNE 2005

"EXTRACTS"



Big pharma approaches The out-licensing of the Company's lead drug candidates in a timely fashion with appropriate financial returns is seen by the Board as a key part of the creation of shareholder value. To this end contact has been established with a number of major pharmaceutical companies, via key decision makers in their oncology or discovery alliance departments. I am pleased to report that the Company is in an advanced stage of discussion and negotiation with a number of majors with the objective of securing option or licence agreements over the next few months. The nature and international standing of those companies reflects growing recognition that EiRx has a strong discovery and development platform coupled to a high degree of scientific excellence and creativity, factors that are crucial in the rapidly moving and highly charged field of drug discovery and development.





Research and development TAKEN FROM INTERIM RESULTS Relised : 31st March 2006

EiRx passed an important milestone in August 2005 with the filing of the company's first patents covering distinct chemical compounds that may be useful in the treatment of cancer. These drug candidates were identified using the Company's EnPADTM screening technology, which enables the discovery of compounds that specifically target the cell survival pathways relied upon by tumours for continued growth and viability. In January of 2006, the Company announced a second patent application describing another series of compounds identified with the use of EnPADTM. Both these patent applications describe series of novel compounds that selectively kill colorectal and breast cancer cells in vitro. The filing of so-called "Medicament" patents describing medicinal use of discrete compound classes is a key measure of our success in transitioning the Company from a basic research laboratory and contract service provider into a drug development business with its own portfolio of candidate anti-cancer therapeutics. In March 2006 the Company announced that it had selected a lead compound for further exploration as a treatment for colorectal and breast cancers, and signed a manufacturing agreement aimed at producing sufficient material to continue pivotal efficacy and safety testing. Our EnPADTM technology was developed with support from the Marie Curie Transfer Of Knowledge grant from the European Union, and approximately ?350,000 of this funding remains for its further development. We anticipate similar productivity from new EnPADTM programmes targeting other important aspects of tumour cell biology. In March 2006 we announced the initiation of a new EnPADTM programme targeting the PI3/ AKT pathway, which is known to play a central role in tumour formation.





For immediate release

19 September 2006 EIRX THERAPEUTICS PLC ("EiRx" or "the Company")

A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies Cork, Ireland - EiRx Therapeutics plc (AIM: ERX), the drug discovery company developing targeted therapies for cancer, is pleased to announce the results of preclinical studies, including preliminary in vivo animal efficacy for its lead compound ERX3722.

A lead series of molecules (which included ERX3722) was identified from a screen of kinase inhibitors using EiRx's EnPad(TM)technology. In cell line based in vitro studies, these molecules demonstrated selective killing of breast cancer cells over non-cancerous breast cells. Following a patent application in August 2005, ADME (Administration, Distribution, Metabolism, Excretion) studies identified ERX3722 (Mw 331) as having favourable drug like properties in terms of metabolic stability, serum binding, P-gp inhibition, Caco-2 efflux, and Cyp450 inhibition.

The compound is also very well tolerated with little or no toxic effects on normal tissues detected, in maximum tolerated dose studies. For the in vivo efficacy studies, mice bearing a subcutaneous human breast cancer xenograft were treated with the compound at several different dosing regimens. All treatment groups responded with a reduction in tumour volume, relative to the untreated control, with the higher doses achieving a very significant 50% reduction in tumour volume. In addition to this significant efficacy, it was observed that during the treatment regime, the mice did not show any toxic or side effects, such as weight loss, associated with compound administration. This suggests that the compound is highly selective for the tumour, unlike the more traditional cancers therapies, where effectiveness can be limited due to associated toxicities.

"A reduction in tumour volume of 50% is seen by the National Cancer Institute in America, and other leading authorities as being highly significant" said Professor Tom Cotter, founder and CSO of EiRx. "We are now in active discussions with a developmental company to further develop this molecule and to prepare it for a future phase 1 clinical trial. Commenting on the results, Dr. Finbarr Murphy, Managing Director of operating subsidiary EiRx Therapeutics Ltd, said: "The efficacy and selectivity of the molecule is very encouraging, and supports our approach of targeted apoptosis therapy in the treatment of cancer to limit toxicity and side effects associated with standard chemotherapy. Across the seven major markets, 443,000 women were estimated to have developed breast cancer in 2004, with an estimated 112,000 dying from the disease. The incidence is forecast to increase annually at an average rate of 3%. The size of the market for breast cancer drugs is $6.2 billion; representing 17% of the total spend of the cancer market.

A great little company with great potential, this is just a snap shot of EiRX


http://www.advfn.com/stocks/eirx-therapeutics-erx-chart-and-discussion-thread-moderated_12957997.html

Even though PH over exaggeraites i do think that ERX is starting to build up on RNS thats due.

Marcel, agree we should get something soon :)

Marcel1970
An rns is over due going by past announcements, they will get the Results out of the way first that are due this month or make some positive statements with in them.

Looking forward to it.

Fair bit of share volume and a tick up.

Must confess i've topped up today couple of times.

Marcel
It must have been your 2x1m buys that did it then.

My buys were all @0.0029

A Tick up 2 days on the run can we make it 3 fingers crossed.

Lets hope so, but if not driver can buy us all a pint saturday night !! :))

0
If it takes off Marcel can buy the pints the amount of stock he holds.

yes Good idea driver ! :)

Luckypicker - 14 Dec'06 - 17:03 - 15855 of 15857


"Colin Telfer"
14/12/2006 16:18
To
cc

Subject
RE: Your recent contact with John Pool, EiRx Therapeutics





Dear Mr XXX,

Yes, I answered an e-mail from a shareholder this morning to say that we
aim to release the annual report next Friday 22nd December. Final
touches are being tied up with the auditors now.

There is no problem with the printers. Print copies will be sent out to
shareholders upon publication of the results.

Regards,

Colin Telfer

PH should be the biggest winner as he holds 35mil + but if this gets to 1p i would gladly buy you 10 pints each.

marcel i ,m only holding 5m how many pints can i have ?

PH probably holds bugger all and works for pence for his boss

zscrooge, probably right :)